Exubrion Therapeutics
Board of Directors

A seasoned and highly-experienced team

At Exubrion, our Board of Directors bring a broad range of experience across numerous therapeutic and business areas to our team.

Mr. Dennis Steadman

Mr. Dennis Steadman

Chairman of the Board, Exubrion Therapeutics™

Dennis F. Steadman is a business leader and entrepreneur with a 35+ year record of success. An experienced animal health executive, Steadman was the founder, Director and CEO of Velcera, Inc., a pet health company that he led from concept and capital funding to operational excellence and acquisition by a NYSE-listed multinational for $160 million in cash. Prior to Velcera, he held executive positions, including: Vice President, North American Operations and Global Management Committee Member with Merial Ltd., a leading animal health company, multiple domestic; international and global executive positions with Merck animal health; and more than a decade as Vice President and Senior Economist with a consulting subsidiary of Chase Manhattan Bank. Steadman holds a master’s degree in Agricultural Economics and a bachelor’s degree in Business Management from the Pennsylvania State University and has completed the Executive Program in Finance at the Harvard Business School.

In addition to providing strategic advisory serves, Steadman serves as a Senior Advisor to AgriCapital Corporation, an investment banking firm focused on Agribusiness and is director and treasurer of BACKED-by-SCIENCE, Inc., a company developing athletic training and performance products. Steadman also serves on the board of Dress For Success, Mercer County, a non-profit helping disadvantaged women enter/reenter the work force.

Mr. Immanuel Thangaraj

Mr. Immanuel Thangaraj

Managing Director, Essex Woodlands Health Ventures, Inc.

Immanuel Thangaraj joined EW in 1998, and serves as Managing Director of the firm’s legacy venture capital funds Essex Woodlands Funds IV, V, VI, VII and VIII.

Mr. Thangaraj has 20 years of experience as a seasoned investor in operations, venture capital and growth equity opportunities. He began his career at ARCH Venture Partners (“AVP”), a leading venture capital firm with over $2 billion under management which makes early stage technology and healthcare investments. During his tenure at AVP, he managed one of its portfolio companies, HealthQual, a medical information company, until its sale to Nellcor, a large hospital supplies company. He left AVP in 1995 to run a start-up telecommunications services company called Integrated Telemanagement, which was later sold to Cam-Net Communications.

Mr. Thangaraj serves on the Board of Directors for Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), Serene, Kona Medical, Inc., and Proteus Digital Health. In addition to the portfolio company boards on which he serves, Immanuel was also responsible for EW’s investment in Microport Scientific Corporation (HK:853); China Cord Blood Services Corporation (NYSE: CO); VenturePharm; CBR Systems (acquired by GTCR); iKnowMed Systems (acquired by NYSE: MCK); and Novacept (acquired by NASDAQ: HOLX).

He serves as the Co-Chair of the Council of the Booth School of Business and the Visiting Committee of the College, both at the University of Chicago. He is also a Trustee of Trinity School in Menlo Park, California; on the Board of the India Community Center in Milpitas, California; and the former Chairman of MAP International.

Mr. Thangaraj holds both a Bachelor of Arts degree and a Master of Business Administration degree from the University of Chicago.

Dr. Rob Readnour

Dr. Rob Readnour

Managing Director, Mountain Group Partners

Rob Readnour - Dr. Readnour currently serves on or has visitation rights to the following companies: AgTech Accelerator, a unique startup accelerator focused on discovering and developing emerging agricultural technology companies; Skyline Vet Pharma, a company that is developing veterinary pharmaceuticals using proven delivery technologies to reformulate drugs with established animal health markets; Boragen, a company that is developing small molecule approaches focused on leveraging the unique chemical properties of boron chemistry, both in crop protection and animal health; Applied LifeSciences & Systems Poultry, a poultry vaccine delivery device company developing a high-throughput vaccine delivery system to individually vaccinate post-hatch chicks; and Convetra, a company developing a radiosynoviorthesis product to treat chronic osteoarthritis in dogs.

Prior to joining MGP, Dr. Readnour worked at Elanco Animal Health for 27 years. During his Elanco tenure, he held several senior management positions in which he was responsible for developing and executing Elanco’s Research and Development strategies for entering several new business areas (companion animal pharmaceuticals, vaccines and enzymes). In 2017, these new business areas accounted for nearly 50% of Elanco’s $3.0 billion in sales. Dr. Readnour played an important role in Elanco’s acquisition and integration of Novartis Animal Health, Lohmann Animal Health, ChemGen and Janssen Animal Health. Within Elanco, Dr. Readnour led several initiatives to transform Research and Development through the piloting of new approaches to developing animal health products. He developed and led Elanco’s new technology scouting, acquisition and due diligence efforts. He pioneered a lean product development model which allowed Elanco to enter new areas of business without significant capital investment. He led initial efforts for Elanco to invest in early stage companies and partner with external funding sources to develop products with minimal initial investment from Elanco. Dr. Readnour served as a member of the Food and Agriculture Section of Bio International Board and as an External Advisory Board member for University of Illinois Animal Science Department.

Prior to entering management in Elanco, Dr. Readnour was an internationally recognized expert on animal health product development, analytical chemistry, human food safety and drug residues with 11 publications and 14 external presentations. Throughout his career, Dr. Readnour was responsible for the development and commercialization of 10 animal health products. Dr. Readnour received his PhD in Analytical Chemistry from University of Illinois in 1990.

Dr. Mark Pykett

Dr. Mark Pykett

Chief Scientific Officer, PTC Therapeutics

Mark Pykett, V.M.D., Ph.D., has been promoted to Chief Scientific Officer, a role in which he leads the research initiatives of PTC. Dr. Pykett joined PTC as part of the acquisition of Agilis Pharmaceuticals, where he served as CEO. Mark has over 20 years of leadership in R&D. Dr. Pykett held senior executive roles and directorships at several public and private companies focused on a range of therapeutic areas, indications and products. Dr. Pykett received his B.A. degree in Biology from Amherst College, a Ph.D. and V.M.D. from the University of Pennsylvania, and an M.B.A. fromNortheastern University, and completed post-doctorate fellowships at the University of Pennsylvania andHarvard University.

Mr. Peter Selover

Ms. Julia Stephanus

President, Avviare Consulting

Julia A. Stephanus is president and founder of Avviare Consulting. Avviare is a consulting practice designed to assist start-ups and established players in the field of veterinary biopharmaceuticals. Prior to this role, Julia served as the Chief Commercial Officer of Aratana Therapeutics, Inc. Ms. Stephanus has more than 25 years’ experience in the pharmaceutical industry, where she is closely involved in the commercial development and launch of breakthrough animal health care drugs such as Rimadyl® and Revolution®. From September 2010 to December 2012, Ms. Stephanus served as a Director of The Global Pet Franchise for Ceva Animal Health, where she oversaw the commercial development of new products as well as global marketing for strategic pet products. In 2006, Ms. Stephanus founded Summit VetPharm, the developer of Vectra, a pet parasiticide product line, and served as its President and Chief Executive Officer until it was acquired by Ceva Animal Health in August 2010. Prior to founding Summit VetPharm, Ms. Stephanus worked in various sales and marketing positions for Pfizer Inc. and its legacy companies, where she had the commercial responsibility for, among other things, the development and global launch of two highly-profitable pet products. Ms. Stephanus received a B.A. from Indiana University and has attended executive education programs at Harvard, Columbia and the Wharton School of Business at the University of Pennsylvania.


Mr. Peter Selover

Chief Executive Officer, Exubrion Therapeutics™

Peter (“Pete”) leads the Exubrion team with 25 years of experience in human and animal health, having served as VP, Corporate Development & Strategy for Merial Ltd. and as Principal at Oriole Advisors, a consulting and venture firm that provides strategy and product and business development advice to new and growing animal health businesses.

He holds a BS in Electrical Engineering from Purdue University and a Master of International Business Studies from the University of South Carolina.

Some of Pete’s favorite pets have included Muffett, a loveable collie mix, and Motorola, a friendly tabby cat.

Synovetin OA™ delivers sustained OA pain relief.1

Synovetin OA™ provides targeted, non-systemic therapy.2


  1. Data on file, Exubrion Therapeutics.
  2. Donecker JM, Fox SM. Safety and effectiveness of Synovetin OA™: Results of three randomized trials evaluating treatment of naturally occurring canine elbow osteoarthritis. Exubrion Therapeutics, July 2019.